现实世界治疗模式和可切除早期非小细胞肺癌患者的相关结果:THASSOS国际研究
Kumar Prabhash1, Rebecca Moor2, Tuncay Göksel3
1Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
Thoracic cancer
|April 24, 2025
概括
这项关于早期非小细胞肺癌 (NSCLC) 的研究发现辅助疗法使用与指导方针一致,但新辅助疗法未得到充分利用. 生物标志物测试水平较低,影响了新疗法之前的治疗决策.
科学领域:
- 在瘤学瘤学.
- 临床研究 临床研究
- 公共卫生 公共卫生
背景情况:
- 萨索斯-INTL研究 (NCT04808050) 是一个跨国,回顾性分析.
- 它研究了亚太地区,中东和非洲早期非小细胞肺癌 (NSCLC) 的治疗模式和结果.
研究的目的:
- 评估早期NSCLC的治疗策略和患者结果.
- 为了确定治疗使用和生存率的趋势.
主要方法:
- 对755名可切除NSCLC (临床阶段IA-IIIB) 的成年患者进行了回顾性分析.
- 从2013年1月1日至2020年12月31日期间收集的数据.
- 随访直到死亡,最后一次访问或数据切断.
主要成果:
- 82.9%的患者进行了手术;39.1%仅接受了手术.
- 辅助疗法用于51.1%,而新辅助疗法用于21.1%.
- 三年生存率为77.4%,平均总生存率为7.5年,辅助治疗最高.
结论:
- 辅助疗法的使用超过了50%,符合指导方针,但新辅助疗法的使用低于最佳水平.
- 较低的生物标志物测试率 (EGFR,PD-L1) 反映了研究期在广泛的向/免疫疗法之前.
- 多学科的方法对于优化治疗决策和改善早期NSCLC患者的治疗结果至关重要,特别是新兴疗法.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
4.8K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Survival Analysis
298
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
298
